Foghorn Therapeutics Inc. (FHTX) Net Cash Provided by (Used in) Financing Activities USD 2020 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Foghorn Therapeutics Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2020 to 2024.
  • Foghorn Therapeutics Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $1.17 M, a 1044% increase year-over-year.
  • Foghorn Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $1.78 M, a 0.85% increase from 2022.
  • Foghorn Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1.76 M, a 92.1% decline from 2021.
  • Foghorn Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $22.4 M, a 89.7% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $1.17 M +$1.07 M +1044% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q1 2023 $102 K -$282 K -73.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q1 2022 $384 K +$322 K +519% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q1 2021 $62 K -$185 K -74.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 $247 K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.